Colorectal Cancer | Specialty

Management of Liver-Dominant Unresectable Colorectal Cancer

February 10th 2017

Neoadjuvant/Adjuvant Approaches in Colorectal Cancer

February 10th 2017

Curative Intent in Oligometastatic Colorectal Cancer

February 10th 2017

MSI Status and Immunotherapy in Advanced Colorectal Cancer

February 10th 2017

Antibody Selection and Right- Versus Left-Sided Colorectal Cancer

February 10th 2017

Understanding Tumor Sidedness in Colorectal Cancer

February 10th 2017

Dr. Loaiza-Bonilla on Trial of Left- and Right-Sided Colorectal Cancer

February 9th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specializing in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses a clinical trial focused on the differences between left- and right-sided tumors of colorectal cancer (CRC).

Expert Discusses PD-1 Success in MSI-H Colorectal Cancer

February 9th 2017

Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.

Atezolizumab/Bevacizumab Combo Attains 90% DCR in MSI-High mCRC

February 7th 2017

Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.

Napabucasin Linked With Objective Responses in Advanced CRC

February 7th 2017

As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab, according to evaluable results of a study presented at the 2017 Gastrointestinal Cancers Symposium.

Dr. Sears on Bacteria Influencing Development of Colon Cancer

February 7th 2017

Cynthia L. Sears, MD, professor of Medicine, Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses bacteria possibly influencing the development of colon cancer.

Enhanced Recovery Program Improves Outcomes After Colorectal Cancer Surgery

February 3rd 2017

The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.

Dr. Muro Discusses Safety Data from Asian XELIRI Project in CRC

February 2nd 2017

Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).

S-1 Better Tolerated Than Capecitabine With No Loss of Efficacy in Metastatic Colorectal Cancer

February 2nd 2017

The incidence of hand-foot syndrome was decreased following first-line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer, according to findings from the phase III SALTO study that were presented at the 2017 European Cancer Congress.

Treatment, Diagnosis Disparities Among Hospitals Impacts Survival of Patients With Colorectal Cancer and Peritoneal Metastases

February 1st 2017

Patients receiving the same diagnosis, colorectal cancer with synchronous peritoneal metastases, were offered different treatments that led to dramatically different outcomes based upon the institution in which they were diagnosed. Findings presented at the 19th European Cancer Congress revealed underutilization of a highly effective treatment, due to a lack of referral.

Dr. Marshall on Molecular Variances Between Right- Versus Left-Sided Colon Cancer

January 30th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, associate director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses molecular variances between right- and left-sided colon cancer.

Dr. Sears on Microbiota in Colon Cancer

January 28th 2017

Cynthia L. Sears, MD, professor of Medicine, at John Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses microbiota in patients with colon cancer.

Vemurafenib Adds to PFS in BRAF-mutant mCRC

January 25th 2017

Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with BRAF-mutant metastatic colorectal cancer.

Dr. Loaiza-Bonilla on Right- Versus Left-Sided Colorectal Cancer

January 24th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specialized in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses findings of patients with right- versus left-sided tumors of colorectal cancer (CRC).

Nivolumab Activity Affirmed in Microsatellite Instability-High mCRC

January 24th 2017

The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.